Abaxis, Inc. (ABAX) Reaches $62.79 52-Week High; Ecolab (ECL) SI Decreased By 0.14%

January 11, 2018 - By Clifton Ray

The stock of Abaxis, Inc. (NASDAQ:ABAX) hit a new 52-week high and has $64.67 target or 3.00% above today’s $62.79 share price. The 7 months bullish chart indicates low risk for the $1.43 billion company. The 1-year high was reported on Jan, 11 by Barchart.com. If the $64.67 price target is reached, the company will be worth $42.75 million more. The stock increased 1.85% or $1.14 during the last trading session, reaching $62.79. About 31,672 shares traded. Abaxis, Inc. (NASDAQ:ABAX) has risen 7.18% since January 11, 2017 and is uptrending. It has underperformed by 9.52% the S&P500.

Ecolab Incorporated (NYSE:ECL) had a decrease of 0.14% in short interest. ECL’s SI was 6.17 million shares in January as released by FINRA. Its down 0.14% from 6.18 million shares previously. With 1.20 million avg volume, 5 days are for Ecolab Incorporated (NYSE:ECL)’s short sellers to cover ECL’s short positions. The SI to Ecolab Incorporated’s float is 2.36%. The stock increased 0.28% or $0.38 during the last trading session, reaching $135.5. About 177,286 shares traded. Ecolab Inc. (NYSE:ECL) has risen 9.41% since January 11, 2017 and is uptrending. It has underperformed by 7.29% the S&P500.

Analysts await Abaxis, Inc. (NASDAQ:ABAX) to report earnings on January, 25. They expect $0.23 earnings per share, down 23.33% or $0.07 from last year’s $0.3 per share. ABAX’s profit will be $5.22M for 68.25 P/E if the $0.23 EPS becomes a reality. After $0.29 actual earnings per share reported by Abaxis, Inc. for the previous quarter, Wall Street now forecasts -20.69% negative EPS growth.

Investors sentiment increased to 1.32 in Q3 2017. Its up 0.20, from 1.12 in 2017Q2. It increased, as 11 investors sold Abaxis, Inc. shares while 36 reduced holdings. 18 funds opened positions while 44 raised stakes. 21.83 million shares or 0.11% less from 21.86 million shares in 2017Q2 were reported. Moreover, Financial Bank Of Montreal Can has 0% invested in Abaxis, Inc. (NASDAQ:ABAX) for 3,902 shares. C M Bidwell And Associates has invested 0.01% of its portfolio in Abaxis, Inc. (NASDAQ:ABAX). Moreover, Mason Street Advsr Ltd Company has 0.01% invested in Abaxis, Inc. (NASDAQ:ABAX). Ahl Prtnrs Ltd Liability Partnership has 11,002 shares. Fred Alger Management has 0.08% invested in Abaxis, Inc. (NASDAQ:ABAX) for 364,539 shares. Citigroup reported 13,074 shares. Texas Permanent School Fund holds 16,565 shares or 0.01% of its portfolio. Morgan Stanley accumulated 103,547 shares or 0% of the stock. Raymond James holds 0.01% in Abaxis, Inc. (NASDAQ:ABAX) or 113,811 shares. Millennium Lc owns 229,154 shares. Vanguard Group holds 0% or 2.03M shares in its portfolio. Brown Capital Management Ltd holds 1.69% or 3.10 million shares in its portfolio. Ameriprise reported 0% in Abaxis, Inc. (NASDAQ:ABAX). Parametric Portfolio Assoc invested 0% of its portfolio in Abaxis, Inc. (NASDAQ:ABAX). Copeland Cap Mgmt Ltd Llc invested in 334,392 shares or 1.01% of the stock.

Abaxis, Inc. develops, manufactures, markets, and sells portable blood analysis systems for use in human or veterinary patient care settings to provide rapid blood constituent measurements for clinicians worldwide. The company has market cap of $1.43 billion. It operates in two divisions, Medical Market and Veterinary Market. It has a 52.76 P/E ratio. The firm offers Piccolo chemistry analyzers with rapid blood constituent measurements for use in human patient care; and Piccolo profiles that are single-use medical reagents.

Among 9 analysts covering Abaxis (NASDAQ:ABAX), 1 have Buy rating, 3 Sell and 5 Hold. Therefore 11% are positive. Abaxis has $72.0 highest and $39 lowest target. $48.33’s average target is -23.03% below currents $62.79 stock price. Abaxis had 24 analyst reports since July 23, 2015 according to SRatingsIntel. Raymond James upgraded the shares of ABAX in report on Tuesday, January 9 to “Hold” rating. The firm has “Hold” rating by Stifel Nicolaus given on Friday, January 27. The company was maintained on Tuesday, June 13 by Canaccord Genuity. The stock of Abaxis, Inc. (NASDAQ:ABAX) has “Hold” rating given on Thursday, October 5 by Canaccord Genuity. The firm has “Buy” rating by Canaccord Genuity given on Thursday, July 23. The company was maintained on Friday, October 27 by Canaccord Genuity. Bank of America maintained Abaxis, Inc. (NASDAQ:ABAX) on Wednesday, October 25 with “Underperform” rating. On Friday, July 22 the stock rating was downgraded by Feltl & Co to “Sell”. Canaccord Genuity maintained it with “Hold” rating and $46.0 target in Monday, August 21 report. The stock has “Hold” rating by Stifel Nicolaus on Monday, October 23.

Since August 3, 2017, it had 1 insider purchase, and 1 insider sale for $9.04 million activity. $10.01 million worth of Ecolab Inc. (NYSE:ECL) was bought by GATES WILLIAM H III on Thursday, August 3. HANDLEY THOMAS W sold $966,233 worth of stock or 7,397 shares.

Ecolab Inc. provides water, hygiene, and energy technologies and services for clients worldwide. The company has market cap of $39.15 billion. The firm operates in three divisions: Global Industrial, Global Institutional, and Global Energy. It has a 30.57 P/E ratio. The Global Industrial segment provides water treatment and process applications, and cleaning and sanitizing solutions primarily to large industrial clients within the manufacturing, food and beverage processing, chemical, mining and primary metals, power generation, pulp and paper, and commercial laundry industries.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: